Clear Your View – An Initiative to ensure all NSCLC patients receive complete biomarker testing before first-line treatment
Home » Clear Your View – An Initiative to ensure all NSCLC patients receive complete biomarker testing before first-line treatment

GH AMEA on Social Media Clear Your View – An Initiative to ensure all NSCLC patients receive complete biomarker testing before first-line treatment
Clear Your View – An Initiative to ensure all NSCLC patients receive complete biomarker testing before first-line treatment
Clear Your View – An Initiative to ensure all NSCLC patients receive complete biomarker testing before first-line treatment
GH AMEA

If you are an oncologist, you’re in the driver’s seat when making treatment decisions for your advanced non-small cell lung cancer (NSCLC) patients. Before making treatment decisions, test for all 10 genomic biomarkers recommended by NCCN. Do not proceed with first-line therapy without a clear view ahead. Liquid biopsies such as the Guardant360 test can help provide you with comprehensive genomic profiling information of your patient’s solid tumor so that you can proceed to recommend the right treatment. Find out more about this initiative at https://clearyourview.org.

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us